학력

1997. 03 ~ 2003. 02 전남대학교 의학과 학사

2004. 03 ~ 2006. 02 전남대학교 의학과 석사

2013. 03 ~ 2015. 08 전남대학교 의학과 박사

펼쳐보기

경력

2003 .03 ~ 2004. 02 전남대병원 인턴

2004. 03 ~ 2008. 02 전남대병원 내과 전공의

2008. 04 ~ 2009. 04 전라남도청보건한방과 병원선 공중보건의

2009. 05 ~ 2011. 04 여수제일병원 공중보건의

2011. 05 ~ 2012. 05 화순전남대병원 혈액종양내과 전임의

2012. 06 ~ 2016. 10 화순전남대병원 혈액종양내과 임상조교수

2016. 11 ~ 2017. 08 화순전남대병원 혈액종양내과 임상부교수

2017. 09 ~ 화순전남대병원 혈액종양내과 기금부교수

펼쳐보기

경력 중 수상경력

2023. 2023 Korean Society of Hematology International Conference & 64th Annual Meeting 대한혈액학회 우수논문상

펼쳐보기

연구업적

2017 3. A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma
Oncotarget 2017, 8; 41538-41548

2017 2. Immunotherapy for the treatment of multiple myeloma
Crit Rev Oncol Hematol 2017;111:87-93

2017 1. A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System
Br J Haematol 2017 (Epub)

2016 3. Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen.
Ann Hematol 2016;95:55-61

2016 2. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression
Ann Hematol 2016;95:1645-51

2016 1. Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen.
BMC cancer 2016;16:613

2015 4. Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment
Blood research 2015;50(3):167-72

2015 3. Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma
Journal of Immunotherapy 2015;38(8):330-9

2015 2. Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma
BMC cancer 2015;15:198

2015 1. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
European Journal of Haematology 2015;94(6):504-10

2014 7. Decreased body mass index is associated with poor prognosis in patients with multiple myeloma
Annals of Hematology 2014,93(5):835-40

2014 6. Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro.
Experimental Hematology 2014;42(4):274-81

2014 5. Advanced lytic lesion is a poor mobilization factor in peripheral blood stem cell collection in patients with multiple myeloma
Journal of Clinical apheresis, 2014;29(6):305-10

2014 4. Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.
Annals of Hematology 2014;93(9):1571-7

2014 3. The impact of hyperglycemia on risk of severe infections during early period of induction therapy in patients with newly diagnosed multiple myeloma
BioMed Research International 2014;2014:413149

2014 2. Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens.
International Journal of Hematology 2014, 100(5):473-7

2014 1. Serum lactate dehydrogenase with systemic inflammation score is a useful indicator to predict response and survival in patients with newly diagnosed diffuse large B-cell lymphoma
Acta Haematologica 2014;133(1):10-7

2013 2. Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide,and dexamethasone) regimen
International Journal of Hematology 2013;97:92-97

2013 1. Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens
International Journal of Hematology 2013;97:382-7

2012 Jung SH, Ahn JS, Yang DH, Chul Park H, Bae SY, Kim YK, Kim HJ, Lee JJ.
Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation.
Case Rep Oncol 2012,5(1),110-3

2012 Park HC, Jung SH, Ahn JS, Kim MY, Yang DH, Kim YK, Kim HJ, Lee JJ.
Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma.
Case Rep Oncol 2012, 5(2),413-9

2007 Jung SH, Shim HJ, Hwang JE, Kim SH, Seo SR, Lim SW, Chung IJ.
A Case of gastric hepatoid adenocarcinoma misdiagnosed as an extragonadal germ cell tumor.
The Korean Journal of Medicien 2007; 73(1); 107~111

2006 Jung SH, Lee JJ, Sohn SK, Shin HJ, Yang DH, Kim YK et al.
Clinical Efficacy of Thalidomide Containing Regimens as a primary Therapy in Patients with Multiple Myeloma.
Korean J Hematol 2006 Jun;41(2):83-91

펼쳐보기

저서

등록된 자료가 없습니다.

펼쳐보기

특허

등록된 자료가 없습니다.

펼쳐보기

학회활동

대한내과학회 정회원

대한혈액학회 정회원

대한조혈모세포이식학회 정회원

펼쳐보기

언론보도

2022. 닌라로 급여 1년 "처방해보니 효과 충분, 다발골수종 치료 포기 줄어" - 화순전남대학교병원 혈액내과 정성훈 교수 / 팜뉴스 / 2022-04-21

펼쳐보기